Glioblastoma: from molecular pathology to targeted treatment.
暂无分享,去创建一个
T. Cloughesy | P. Mischel | W. Cavenee | Timothy F. Cloughesy | Webster K. Cavenee | Paul S. Mischel
[1] Thomas D. Wu,et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.
[2] Debyani Chakravarty,et al. Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response , 2012, Proceedings of the National Academy of Sciences.
[3] James Brugarolas,et al. Renal-cell carcinoma--molecular pathways and therapies. , 2007, The New England journal of medicine.
[4] Joseph Gera,et al. mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor. , 2007, Cancer research.
[5] J. D. de Groot,et al. Mediators of Glioblastoma Resistance and Invasion during Antivascular Endothelial Growth Factor Therapy , 2009, Clinical Cancer Research.
[6] E. Holland,et al. Astrocyte-Specific Expression Patterns Associated with the PDGF-Induced Glioma Microenvironment , 2012, PloS one.
[7] K. Aldape,et al. Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation , 2011, Nature.
[8] R. Stupp,et al. Individualized Targeted Therapy for Glioblastoma: Fact or Fiction? , 2012, Cancer journal.
[9] T. Cloughesy,et al. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. , 2011, Neuro-oncology.
[10] P. Kleihues,et al. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. , 2005, Journal of neuropathology and experimental neurology.
[11] B. Manning,et al. mTOR links oncogenic signaling to tumor cell metabolism , 2011, Journal of Molecular Medicine.
[12] J. Troge,et al. Tumour evolution inferred by single-cell sequencing , 2011, Nature.
[13] S. Horvath,et al. Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma , 2008, PLoS medicine.
[14] H. Christofk,et al. Pyruvate kinase M2 is a phosphotyrosine-binding protein , 2008, Nature.
[15] D. Steindler,et al. Human cortical glial tumors contain neural stem‐like cells expressing astroglial and neuronal markers in vitro , 2002, Glia.
[16] J. Uhm,et al. The transcriptional network for mesenchymal transformation of brain tumours , 2010 .
[17] C. Thompson,et al. The molecular determinants of de novo nucleotide biosynthesis in cancer cells. , 2009, Current opinion in genetics & development.
[18] D. Bigner,et al. Immunotherapy of brain tumors. , 2012, Handbook of clinical neurology.
[19] N. Sonenberg,et al. Signal transduction. Protein synthesis and oncogenesis meet again. , 2006, Science.
[20] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[21] Arturo Alvarez-Buylla,et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. , 2009, Cancer cell.
[22] V. P. Collins,et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics , 2013, Proceedings of the National Academy of Sciences.
[23] Paul S Mischel,et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation , 2010, Proceedings of the National Academy of Sciences.
[24] Webster K. Cavenee,et al. A Drosophila Model for EGFR-Ras and PI3K-Dependent Human Glioma , 2009, PLoS genetics.
[25] L. Cantley,et al. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.
[26] Douglas L Black,et al. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. , 2013, Cell metabolism.
[27] P. Kleihues,et al. Definition of Primary and Secondary Glioblastoma—Response , 2014, Clinical Cancer Research.
[28] W. Cavenee,et al. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[29] T. Cloughesy,et al. Molecular pathology in adult high‐grade gliomas: from molecular diagnostics to target therapies , 2012, Neuropathology and applied neurobiology.
[30] S. Pastorino,et al. Transdifferentiation of glioblastoma cells into vascular endothelial cells , 2011, Proceedings of the National Academy of Sciences.
[31] R. Verhaak,et al. Transformation by the R Enantiomer of 2-Hydroxyglutarate Linked to EglN Activation , 2012, Nature.
[32] Claudio R. Santos,et al. SREBP Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell Growth , 2008, Cell metabolism.
[33] Matthew S. Brown,et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. , 2009, Radiology.
[34] Xuerui Yang,et al. An Extensive MicroRNA-Mediated Network of RNA-RNA Interactions Regulates Established Oncogenic Pathways in Glioblastoma , 2011, Cell.
[35] D. Louis,et al. AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. , 2006, Cancer research.
[36] A. Viale,et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype , 2012, Nature.
[37] Forest M White,et al. Oncogenic EGFR Signaling Networks in Glioma , 2009, Science Signaling.
[38] M. J. van den Bent,et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Yoshitaka Narita,et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. , 2010, Genes & development.
[40] David T. W. Jones,et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.
[41] R. McLendon,et al. IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.
[42] Jason A. Koutcher,et al. Identification of a tumour suppressor network opposing nuclear Akt function , 2006, Nature.
[43] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[44] H. Varmus,et al. Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.
[45] A. Guha,et al. Conditional Astroglial Rictor Overexpression Induces Malignant Glioma in Mice , 2012, PloS one.
[46] H. Woo,et al. Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. , 2013, Cell reports.
[47] D. Louis. WHO classification of tumours of the central nervous system , 2007 .
[48] Susan M. Chang,et al. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. , 2010, Neuro-oncology.
[49] L. Chin,et al. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence , 2010, Proceedings of the National Academy of Sciences.
[50] Rebecca A Betensky,et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. , 2011, Cancer cell.
[51] Paul S Mischel,et al. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. , 2012, Cancer discovery.
[52] R. McLendon,et al. Direct In Vivo Evidence for Tumor Propagation by Glioblastoma Cancer Stem Cells , 2011, PloS one.
[53] J. Rich,et al. Seeing is Believing: Are Cancer Stem Cells the Loch Ness Monster of Tumor Biology? , 2011, Stem Cell Reviews and Reports.
[54] D. Cheresh,et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. , 2012, Cancer cell.
[55] L. Ricci-Vitiani,et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells , 2011, Nature.
[56] J. Goldstein,et al. The SREBP Pathway: Regulation of Cholesterol Metabolism by Proteolysis of a Membrane-Bound Transcription Factor , 1997, Cell.
[57] Qiulian Wu,et al. Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. , 2012, Genes & development.
[58] R. Arceci. Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .
[59] M. Prados,et al. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. , 2011, Cancer discovery.
[60] A. Brandes,et al. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) , 2007, British Journal of Cancer.
[61] Mark W. Dewhirst,et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.
[62] Tracy T Batchelor,et al. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. , 2011, Cancer research.
[63] Rong Fan,et al. Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells , 2011, Proceedings of the National Academy of Sciences.
[64] R. McLendon,et al. Integrin alpha 6 regulates glioblastoma stem cells. , 2010, Cell stem cell.
[65] Eric C. Holland,et al. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice , 2000, Nature Genetics.
[66] E. Gottlieb,et al. The music of lipids: How lipid composition orchestrates cellular behaviour , 2012, Acta oncologica.
[67] S. Gabriel,et al. Epidermal Growth Factor Receptor Activation in Glioblastoma through Novel Missense Mutations in the Extracellular Domain , 2006, PLoS medicine.
[68] S. Hariono,et al. Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. , 2012, Cancer discovery.
[69] R. McLendon,et al. Glioblastoma Stem Cells Generate Vascular Pericytes to Support Vessel Function and Tumor Growth , 2013, Cell.
[70] L. Liau,et al. Recurrent somatic mutation of FAT1 in multiple human cancers leads to aberrant Wnt activation , 2013, Nature Genetics.
[71] J. Uhm. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .
[72] Ivan Babic,et al. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. , 2011, Cancer discovery.
[73] C. Brennan,et al. Glioblastoma Subclasses Can Be Defined by Activity among Signal Transduction Pathways and Associated Genomic Alterations , 2009, PloS one.
[74] M. Lemmon,et al. Occupy EGFR. , 2012, Cancer discovery.
[75] Ivan Babic,et al. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. , 2013, Cancer discovery.
[76] Anne E Carpenter,et al. mTOR Complex 1 Regulates Lipin 1 Localization to Control the SREBP Pathway , 2011, Cell.
[77] Zhaoshi Jiang,et al. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[78] H. Okano,et al. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies , 2013, Proceedings of the National Academy of Sciences.
[79] T. Mikkelsen,et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[80] P. Kleihues,et al. IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas , 2009, Clinical Cancer Research.
[81] T. Graeber,et al. An essential requirement for the SCAP/SREBP signaling axis to protect cancer cells from lipotoxicity. , 2013, Cancer research.
[82] S. Horvath,et al. Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.
[83] Michelle J Hickey,et al. Cellular and vaccine therapeutic approaches for gliomas , 2010, Journal of Translational Medicine.
[84] Eric A Bushong,et al. Dedifferentiation of Neurons and Astrocytes by Oncogenes Can Induce Gliomas in Mice , 2012, Science.
[85] Paul S Mischel,et al. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis , 2009, Proceedings of the National Academy of Sciences.
[86] D. Sabatini,et al. mTOR Signaling in Growth Control and Disease , 2012, Cell.
[87] Yonghong Xiao,et al. microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. , 2012, Cancer discovery.
[88] P. Mischel,et al. Multiple functions of a glioblastoma fusion oncogene. , 2013, The Journal of clinical investigation.
[89] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[90] A. Guha,et al. Mouse Models to Interrogate the Implications of the Differentiation Status in the Ontogeny of Gliomas , 2011, Oncotarget.
[91] S. Gabriel,et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.
[92] R. McLendon,et al. Laminin alpha 2 enables glioblastoma stem cell growth , 2012, Annals of neurology.
[93] F. Davis,et al. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. , 2001, Neuro-oncology.
[94] D. Zagzag,et al. Mechanisms of glioma-associated neovascularization. , 2012, The American journal of pathology.
[95] L. Liau,et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.
[96] D. Sabatini,et al. mTOR Signaling. , 2012, Cold Spring Harbor perspectives in biology.
[97] Anderson. Nonmetabolic functions of pyruvate kinase isoform M2 in controlling cell cycle progression and tumorigenesis , 2012 .
[98] E. Holland,et al. Genetic modeling of gliomas in mice: New tools to tackle old problems , 2011, Glia.
[99] M. Assanah,et al. HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer , 2010, Nature.
[100] David T. W. Jones,et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.
[101] R. Stupp,et al. Decision making and management of gliomas: practical considerations. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[102] Dawen Zhao,et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. , 2005, Cancer cell.
[103] P. Ward,et al. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.
[104] D. Housman,et al. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis , 2009, Proceedings of the National Academy of Sciences.
[105] Rong Wang,et al. Glioblastoma stem-like cells give rise to tumour endothelium , 2010, Nature.
[106] C. James,et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel , 2007, Molecular Cancer Therapeutics.
[107] D. Brat,et al. Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma , 2012, Science.
[108] T. Golub,et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.
[109] W. Cavenee,et al. Heterogeneity maintenance in glioblastoma: a social network. , 2011, Cancer research.
[110] Carlo C. Maley,et al. Clonal evolution in cancer , 2012, Nature.
[111] H. Fine,et al. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. , 2009, Cell stem cell.
[112] Ioan Tabus,et al. Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays , 2006, Proteomics.
[113] Keith L. Ligon,et al. Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.
[114] E. Lander,et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.
[115] M. Nykter,et al. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma. , 2013, The Journal of clinical investigation.
[116] Qicheng Ma,et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. , 2010, Molecular cell.
[117] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[118] Miriam Scadeng,et al. Development of a novel mouse glioma model using lentiviral vectors , 2009, Nature Medicine.
[119] Daniel H. Geschwind,et al. Cancerous stem cells can arise from pediatric brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[120] John A Butman,et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] R. Wilson,et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. , 2010, Cancer cell.
[122] T. Golub,et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways , 2004, Nature Medicine.
[123] Tzong-Shiue Yu,et al. A restricted cell population propagates glioblastoma growth after chemotherapy , 2012 .
[124] Gordon B Mills,et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.
[125] Sang Gyun Kim,et al. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation , 2008, Proceedings of the National Academy of Sciences.
[126] C. James,et al. Akt and Autophagy Cooperate to Promote Survival of Drug-Resistant Glioma , 2010, Science Signaling.
[127] R. DePinho,et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. , 2002, Cancer cell.
[128] L. Chin,et al. Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities. , 2006, Cancer research.
[129] P. Sorger,et al. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.
[130] Chunxu Qu,et al. Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. , 2011, Cancer cell.
[131] Koji Yoshimoto,et al. Distinct transcription profiles of primary and secondary glioblastoma subgroups. , 2006, Cancer research.
[132] K. Aldape,et al. NFKBIA deletion in glioblastomas. , 2011, The New England journal of medicine.
[133] J. Stamler,et al. Glioma Stem Cell Proliferation and Tumor Growth Are Promoted by Nitric Oxide Synthase-2 , 2011, Cell.
[134] P. Kleihues,et al. The Definition of Primary and Secondary Glioblastoma , 2012, Clinical Cancer Research.
[135] K. Aldape,et al. The Use of Global Profiling in Biomarker Development for Gliomas , 2011, Brain pathology.
[136] Ru Wei,et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth , 2008, Nature.
[137] A. Harris,et al. Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth , 2013, Cancer & Metabolism.
[138] B. Turk,et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. , 2008, Molecular cell.
[139] B. Viollet,et al. Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy , 2011, Science.
[140] S. Horvath,et al. Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples , 2008, Clinical Cancer Research.
[141] S. Vandenberg,et al. Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240 , 2012, Proceedings of the National Academy of Sciences.
[142] N. Sonenberg,et al. Protein Synthesis and Oncogenesis Meet Again , 2006, Science.
[143] Rosa Bernardi,et al. PML inhibits HIF-1α translation and neoangiogenesis through repression of mTOR , 2006, Nature.
[144] I. Bayazitov,et al. A perivascular niche for brain tumor stem cells. , 2007, Cancer cell.
[145] Paul S Mischel,et al. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. , 2003, Cancer research.
[146] R. Henkelman,et al. Identification of human brain tumour initiating cells , 2004, Nature.
[147] J. Barnholtz-Sloan,et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.
[148] D. Louis. The next step in brain tumor classification: “Let us now praise famous men”… or molecules? , 2012, Acta Neuropathologica.
[149] J. Licht,et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.
[150] C. Brennan,et al. Perivascular nitric oxide activates notch signaling and promotes stem-like character in PDGF-induced glioma cells. , 2010, Cell stem cell.
[151] Michael Weller,et al. Standards of care for treatment of recurrent glioblastoma--are we there yet? , 2013, Neuro-oncology.
[152] R. Deberardinis,et al. Analysis of tumor metabolism reveals mitochondrial glucose oxidation in genetically diverse human glioblastomas in the mouse brain in vivo. , 2012, Cell metabolism.
[153] Kornelia Polyak,et al. Cellular heterogeneity and molecular evolution in cancer. , 2013, Annual review of pathology.
[154] K. Aldape,et al. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. , 2012, Nature cell biology.
[155] K. Aldape,et al. EGFR-induced and PKCε monoubiquitylation-dependent NF-κB activation upregulates PKM2 expression and promotes tumorigenesis. , 2012, Molecular cell.
[156] W. Yung,et al. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. , 2010, Neuro-oncology.
[157] Sally Freels,et al. Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. , 2010, Neuro-oncology.
[158] S. Pannullo,et al. Phase I/II study of oral erlotinib for treatment of relapsed/refractory glioblastoma multiforme and anaplastic astrocytoma. , 2012, Journal of experimental therapeutics & oncology.
[159] S. Horvath,et al. EGFR Signaling Through an Akt-SREBP-1–Dependent, Rapamycin-Resistant Pathway Sensitizes Glioblastomas to Antilipogenic Therapy , 2009, Science Signaling.
[160] Omar Abdel-Wahab,et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.
[161] Lynda Chin,et al. Emerging insights into the molecular and cellular basis of glioblastoma. , 2012, Genes & development.
[162] D. Guertin,et al. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.
[163] S. Berger,et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.